Arbutus Biopharma

Arbutus Biopharma announced a modified tender offer using a Dutch-auction process to repurchase common shares of up to $230 million at prices between $5.00 and $5.75 per share, expected to run from about Aug. 24 to Sept. 29, 2026. The program will be fully funded from existing cash, partly stemming from a $950 million upfront payment from Moderna after a patent settlement. The announcement pushed the stock up nearly 9.8% and led to a 52-week high; Arbutus is also continuing patent litigation against Pfizer and BioNTech. » More on de.investing.com

Arbutus announces a modified tender offer using a Dutch auction process to repurchase its common shares for up to $230 million. Shareholders may tender shares at a price between $5.00 and $5.75 per share; the offer is expected to begin around the coming Monday and to close on September 29, 2026. The repurchase will be funded from existing cash, including a payment received in July under a settlement with Moderna. The offer is subject to required exemptions in Canada and the U.S.; J.P. Morgan Securities is acting as dealer‑manager. » More on de.investing.com

Arbutus and licensee Genevant have filed three international lawsuits against Pfizer and BioNTech alleging infringement of lipid nanoparticle (LNP) patents, including a suit in the Federal Court of Canada and two proceedings before the Unified Patent Court in Europe. They seek permanent injunctions and damages for mRNA-LNP COVID-19 vaccines; parallel proceedings are already underway in the U.S. District Court in New Jersey. Arbutus recently received about $178 million from Moderna in a settlement, plans up to $230 million in share buybacks starting in Q3 2026 and expects a dividend from Genevant; the company reports strong margins and a P/E ratio of 5.45. » More on de.investing.com